Catalyst Event
Gilead Sciences Inc (GILD) · Other
From KEDI U.S. Tech100 90% Participation + Daily Options Premium Index (KUSTC100P)
3/23/2026, 12:00:00 AM
Gilead is reported to be in advanced negotiations to acquire Ouro Medicines, a biotech firm specializing in autoimmune diseases, for up to $2 billion; high importance is estimated based on the significant strategic value of the acquisition.
Korean Translation
길리어드가 자가면역질환 전문 바이오텍 회사인 오우로 메디슨스를 최대 20억 달러에 인수하기 위한 막바지 협상 단계에 있는 것으로 보도됨. 인수의 전략적 가치를 고려할 때 높은 중요도가 예상됨.
Related Recent Events
Adobe Inc (ADBE) · Earnings Release
Adobe's Q2 2026 earnings release is scheduled for June 12, 2026, which is expected to have a high market impact (>=10%) as it provides the next official update on financial performance scheduled.
6/12/2026, 12:00:00 AM
Biogen Inc (BIIB) · Other
U.S. FDA decision on LEQEMBI IQLIK (subcutaneous) for treatment initiation is scheduled. The FDA granted Priority Review for this supplemental Biologics License Application, with a PDUFA action date of May 24, 2026, which is expected. This event is expected to have a high price impact due to the significant market potential of the new delivery method.
5/24/2026, 12:00:00 AM
Rocket Lab Corp (RKLB) · Earnings Release
The next quarterly earnings release on 2026-05-14 is scheduled.
5/14/2026, 12:00:00 AM
COINBASE GLOBAL INC (COIN) · Earnings Release
Coinbase's Q1 2026 earnings release is scheduled for May 7, 2026. Medium importance is estimated as earnings reports are significant events that typically lead to price adjustments, scheduled.
5/7/2026, 12:00:00 AM
Fortinet Inc (FTNT) · Earnings Release
Fortinet's Q1 2026 earnings release is expected on April 30, 2026. Analysts forecast EPS of approximately $0.62 on revenue of $1.73 billion. Medium importance is estimated as earnings releases typically drive significant price movement, estimated.
4/30/2026, 12:00:00 AM
Western Digital Corp (WDC) · Earnings Release
Fiscal third-quarter 2026 earnings release on April 29, 2026, is scheduled. Analysts forecast strong year-over-year growth, with consensus EPS estimates around $2.30-$2.34 forecasted. High impact (≥10%) is estimated and scheduled.
4/29/2026, 12:00:00 AM